What happened on the stock market today?

<p class = "canvas-atom web-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Stocks fell on Monday at the fear of d & # 39; a trade deal with China will not happen soon eclipsed the news of an increase in consumer confidence in the US. & nbsp;Dow Jones Industrial Average (DJINDICES: ^ DJI)& nbsp; and the & nbsp;S & amp; P 500 (SNPINDEX: ^ GSPC)& nbsp; opened up but dropped in the afternoon to close at the low of the session. "data-reactid =" 11 "> Stocks fell on Monday, fearing that a trade deal will be struck with China soon overshadowed the rise in consumer confidence in the United States Dow Jones Industrial Average (DJINDICES: ^ DJI) and the S & P 500 (SNPINDEX: ^ GSPC) opened higher but sagged in the afternoon to close at the lowest of the session.

Stock Market Today

Data source: Yahoo! Finance.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "As for individual actions, Global payments (NYSE: GPN) and Total system services (NYSE: TSS) announced merger plans, and BioMarin Pharmaceutical (NASDAQ: BMRN) reported positive results for his gene therapy treatment for the treatment of hemophilia A. "data-reactid =" 16 "> As for individual stocks, Global payments (NYSE: GPN) and Total system services (NYSE: TSS) announced merger plans, and BioMarin Pharmaceutical (NASDAQ: BMRN) has reported positive results for his gene therapy treatment for hemophilia A.

Source of the image: Getty Images.

Global Payments and Total Systems Services plan to merge to create a payments giant

<p class = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Consolidation in the payments sector is continued today when Global Payments and Total Systems Services announced & nbsp; they will combine as part of a $ 21.5 billion equity equivalent merger. Shares of Global Payments declined 3% to $ 148.87 and those of Total Systems Services increased 4.8% to $ 118.84. "Data-reactid =" 30 "> Consolidation in the payments sector continues today with the announcement of the merger between Global Payments and Total Systems Services Global Payments shares fell 3% to $ 148.87 and Total Systems Services 4.8% to $ 118.84.

<p class = "canvas-atom-text-canvas Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Shareholders of Total Systems will receive 0.8101 Global Payments shares for each share they own, which corresponds to a 20% premium on Total System's share price as of May 23, just before news of the case have filtered. At closing, the shareholders of Global Payments will own 52% of the amalgamated company. "Data-reactid =" 31 "> The shareholders of Total Systems will receive 0.8101 shares of Global Payments for each share they own, which corresponds to a 20% premium compared to the share of Total System To the closing, the shareholders of Global Payments will own 52% of the merged company.

The new entity will be a payment center that will provide software and payment processing solutions to 3.5 million businesses and 1,300 financial institutions in 100 countries and handle approximately 50 billion transactions annually. The companies expect the transaction to increase earnings per share by 1 to 5% in 2020 and 2 to 10% thereafter, to generate an annual adjusted net income of $ 10 million. approximately $ 8.6 billion.

BioMarin Reports Advances in Gene Therapy for Hemophilia A

<p class = "web-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The biotech specialist BioMarin has published positive results from two studies & nbsp; of his genetical therapy treatment for hemophilia A, but shares slipped 5.1%. The company announced that the results of its Phase 3 study met pre-defined criteria for regulatory review in the US and Europe and provided an update three years after patient follow-up in a Phase 1 study. 2 earlier. Data-reactid = "34"> BioMarin, a specialist in biotechnology, has announced positive results after two studies on the treatment of its treatment of hemophilia A in hemophilia A. The company announced that the results of its Phase 3 study met predefined regulatory criteria in the US and Europe – an update after three years of follow-up of patients from a previous phase 1/2 study.

The treatment, valoctocogene roxaparvovec ("valrox"), transfers to the patient the gene necessary for the production of coagulation factor VIII, which is lacking in patients with hemophilia A. In the phase 3 study, Eight out of 16 patients reached the target level of factor VIII, and in 16 patients, the estimated average annual bleeding rate was 85% lower than the current standard treatment. The phase 1/2 study showed that factor VIII levels decreased in the third year but appeared to plateau, suggesting to society that the effects of treatment should last at least eight years.

BioMarin intends to review the results with the regulatory agencies for submission and expects the approval process to support a launch by the end of the year. of 2020.

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = " More from The Motley Fool "data-reactid =" 37 "> More from The Motley Fool

<p class = "canvas-atom canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Jim Crumly holds shares in BioMarin Pharmaceutical. Motley Fool recommends BioMarin Pharmaceutical. The Motley Fool has a disclosure policy."data-reactid =" 45 ">Jim Crumly holds shares in BioMarin Pharmaceutical. Motley Fool recommends BioMarin Pharmaceutical. Motley Fool has a disclosure policy.